Edwards Lifesciences Files 8-K on Financials
Ticker: EW · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1099800
| Field | Detail |
|---|---|
| Company | Edwards Lifesciences Corp (EW) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Edwards Lifesciences dropped an 8-K detailing its financial results and condition as of Feb 11, 2025.
AI Summary
Edwards Lifesciences Corporation filed an 8-K on February 11, 2025, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing pertains to the period ending February 11, 2025.
Why It Matters
This filing provides crucial updates on Edwards Lifesciences' financial performance and condition, which can impact investor decisions and market perception.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual or significant risks.
Key Players & Entities
- Edwards Lifesciences Corporation (company) — Registrant
- February 11, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Irvine, California (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
What is the reporting period for this 8-K filing?
The Conformed Period of Report is February 11, 2025, and the Date of Report is also February 11, 2025.
Where are Edwards Lifesciences' principal executive offices located?
The principal executive offices are located at One Edwards Way, Irvine, California 92614.
What is the SEC file number for Edwards Lifesciences?
The SEC file number for Edwards Lifesciences is 001-15525.
What is the Standard Industrial Classification (SIC) code for Edwards Lifesciences?
The SIC code is 3842, categorized under 'ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES'.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-02-11 16:24:18
Key Financial Figures
- $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
Filing Documents
- ew-20250211.htm (8-K) — 34KB
- ex-991q42024.htm (EX-99.1) — 472KB
- ew45percentblacklrga21a.jpg (GRAPHIC) — 625KB
- 0001099800-25-000003.txt ( ) — 1512KB
- ew-20250211.xsd (EX-101.SCH) — 2KB
- ew-20250211_lab.xml (EX-101.LAB) — 21KB
- ew-20250211_pre.xml (EX-101.PRE) — 12KB
- ew-20250211_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 11, 2025, Edwards Lifesciences Corporation, a Delaware corporation ("Edwards"), issued a press release setting forth Edwards' financial results for the fourth quarter of 2024. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated February 11, 2025, reporting Edwards' financial results for the fourth quarter of 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 11, 2025 EDWARDS LIFESCIENCES CORPORATION By: /s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer 3 Exhibit Index Exhibit Number Description 99.1 Press release, dated February 11, 2025, reporting Edwards' financial results for the fourth quarter of 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 4